| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/S00105-013-2736-5 |
| P698 | PubMed publication ID | 24903030 |
| P2093 | author name string | C-D Klemke | |
| J P Nicolay | |||
| P2860 | cites work | Ultraviolet A1 phototherapy for mycosis fungoides | Q46104065 |
| Bexarotene therapy for mycosis fungoides and Sézary syndrome. | Q46119707 | ||
| Broad band UVA: a possible reliable alternative to PUVA in the treatment of early-stage mycosis fungoides | Q46184067 | ||
| Prospective multicenter study of pegylated liposomal doxorubicin treatment in patients with advanced or refractory mycosis fungoides or Sézary syndrome | Q46535550 | ||
| Gemcitabine as frontline treatment for cutaneous T-cell lymphoma: phase II study of 32 patients | Q46744850 | ||
| Revisiting low-dose total skin electron beam therapy in mycosis fungoides. | Q46914090 | ||
| Long-term outcome of intravenous therapy with rituximab in patients with primary cutaneous B-cell lymphomas. | Q50882623 | ||
| Rituximab plus liposomal pegylated doxorubicin in the treatment of primary cutaneous B-cell lymphomas. | Q53062088 | ||
| Prospective international multicenter phase II trial of intravenous pegylated liposomal doxorubicin monochemotherapy in patients with stage IIB, IVA, or IVB advanced mycosis fungoides: final results from EORTC 21012. | Q53122623 | ||
| Multicenter study of pegylated liposomal doxorubicin in patients with cutaneous T-cell lymphoma | Q73867868 | ||
| Total skin electron radiation in the management of mycosis fungoides: Consensus of the European Organization for Research and Treatment of Cancer (EORTC) Cutaneous Lymphoma Project Group | Q74662041 | ||
| Increased CCR4 expression in cutaneous T cell lymphoma | Q78672866 | ||
| TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the Cutaneous Lymphoma Task Force of the European Organization of | Q79880342 | ||
| Narrowband UVB phototherapy for early-stage mycosis fungoides: evaluation of clinical and histopathological changes | Q80086576 | ||
| Mirtazapine and gabapentin for reducing pruritus in cutaneous T-cell lymphoma | Q80110797 | ||
| Results of radiotherapy in 153 primary cutaneous B-Cell lymphomas classified according to the WHO-EORTC classification | Q80217283 | ||
| Radiation therapy in the management of unilesional primary cutaneous T-cell lymphomas | Q82383994 | ||
| Primary cutaneous diffuse large B-cell lymphoma, leg-type, treated with a modified R-CHOP immunochemotherapy - diagnostic and therapeutic challenges | Q82688172 | ||
| Isolated limb perfusion with melphalan for the treatment of intractable primary cutaneous diffuse large B-cell lymphoma leg type | Q83180706 | ||
| PUVA plus interferon α2b in the treatment of advanced or refractory to PUVA early stage mycosis fungoides: a case series | Q84498470 | ||
| Rituximab for primary cutaneous diffuse large B-cell lymphoma-leg type | Q85213804 | ||
| Lenalidomide monotherapy in relapsed primary cutaneous diffuse large B cell lymphoma-leg type | Q86813220 | ||
| Localized conventional radiotherapy in the treatment of Mycosis Fungoides: our experience in 100 patients | Q87348496 | ||
| Doxorubicin cardiomyopathy | Q24606920 | ||
| The optimal use of bexarotene in cutaneous T-cell lymphoma | Q28305252 | ||
| Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part II. Prognosis, management, and future directions | Q28306039 | ||
| Multicenter phase II study of bendamustine plus rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma | Q33407529 | ||
| Bendamustine combined with rituximab for patients with relapsed or refractory diffuse large B cell lymphoma | Q33409872 | ||
| Symptomatic treatment of interferon-α-induced depression in hepatitis C: a systematic review | Q34313334 | ||
| Primary cutaneous B-cell lymphomas: part II. Therapy and future directions | Q34365013 | ||
| WHO-EORTC classification for cutaneous lymphomas | Q34391006 | ||
| Human anti-CCR4 minibody gene transfer for the treatment of cutaneous T-cell lymphoma. | Q34413695 | ||
| The use of antidepressant drugs in dermatology | Q34529472 | ||
| Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment | Q34633209 | ||
| European Organization for Research and Treatment of Cancer and International Society for Cutaneous Lymphoma consensus recommendations for the management of cutaneous B-cell lymphomas | Q34787789 | ||
| How I treat mycosis fungoides and Sézary syndrome | Q34998601 | ||
| Humanization of an anti-CCR4 antibody that kills cutaneous T-cell lymphoma cells and abrogates suppression by T-regulatory cells | Q36392832 | ||
| EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome. | Q36436109 | ||
| Minimizing adverse side-effects of oral bexarotene in cutaneous T-cell lymphoma: an expert opinion | Q36553825 | ||
| Mycosis fungoides: a dermatological masquerader. | Q36697655 | ||
| Cutaneous lymphoma incidence patterns in the United States: a population-based study of 3884 cases | Q37201934 | ||
| The Stanford University experience with conventional-dose, total skin electron-beam therapy in the treatment of generalized patch or plaque (T2) and tumor (T3) mycosis fungoides | Q37876038 | ||
| Narrowband UVB as an effective substitute for psoralen plus UVA: lessons from a psoralen shortage | Q38042739 | ||
| Cutaneous B-cell lymphomas: 2013 update on diagnosis, risk-stratification, and management | Q38078943 | ||
| Treatment and outcomes in patients with primary cutaneous B-cell lymphoma: the BC Cancer Agency experience | Q38133878 | ||
| Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part I. Diagnosis: clinical and histopathologic features and new molecular and biologic markers | Q38179568 | ||
| Recent advances in primary cutaneous B-cell lymphomas | Q38181880 | ||
| Low-dose total skin electron beam therapy as a debulking agent for cutaneous T-cell lymphoma: an open-label prospective phase II study. | Q39701541 | ||
| Cutaneous lymphomas in Germany: an analysis of the Central Cutaneous Lymphoma Registry of the German Society of Dermatology (DDG). | Q40189634 | ||
| Phase II evaluation of gemcitabine monotherapy for cutaneous T-cell lymphoma. | Q40473507 | ||
| Low-dose methotrexate to treat erythrodermic cutaneous T-cell lymphoma: results in twenty-nine patients | Q40970585 | ||
| Combined treatment with rituximab and anthracycline-containing chemotherapy for primary cutaneous large B-cell lymphomas, leg type, in elderly patients | Q43190635 | ||
| Gemcitabine as single agent in pretreated T-cell lymphoma patients: evaluation of the long-term outcome. | Q43249154 | ||
| Long-term experience with low-dose interferon-alpha and PUVA in the management of early mycosis fungoides | Q43797354 | ||
| Optimizing bexarotene therapy for cutaneous T-cell lymphoma | Q44194042 | ||
| Serum soluble interleukin-2 receptor (sIL-2R) level is associated with the outcome of patients with diffuse large B cell lymphoma treated with R-CHOP regimens | Q44892511 | ||
| Improvement in peripheral blood disease burden in patients with Sézary syndrome and leukemic mycosis fungoides after total skin electron beam therapy | Q45796461 | ||
| Treatment of cutaneous B-cell lymphoma, leg type, with age-adapted combinations of chemotherapies and rituximab. | Q46086772 | ||
| P433 | issue | 7 | |
| P304 | page(s) | 607-613 | |
| P577 | publication date | 2014-07-01 | |
| P1433 | published in | Die Dermatologie | Q15756740 |
| P1476 | title | [Management of cutaneous lymphomas] | |
| P478 | volume | 65 |
Search more.